Predictors of Response to Iron and Erythropoietin Stimulating Agents

Imperial College London197 enrolled

Overview

The purpose of the study is to identify predictors of treatment response. This involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment. A positive outcome following treatment was defined as an uptitration of haemoglobin by greater than 5g/l within 2 months. The study evaluated the participants response to treatment against the clinical and biochemical information collected prior to treatment being received.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

197

Conditions

Renal Failure Chronic Anemia

Interventions

Iron Sucrose Solution for InjectionDRUG

200mg iron sucrose given on 5 successive haemodialysis sessions

Epoetin BetaDRUG

Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All prevalent haemodialysis patients, established for greater than 3 months Exclusion Criteria: Inability to consent Bone marrow disorder Transfusion dependence Active bleeding Active infection Active malignancy Frail with either frequent hospital admissions or unable to follow trial protocol due to differing target haemoglobin

Outcomes

Primary Outcomes

Hemoglobin Incrementation

Incrementation of haemoglobin of 5g/l following treatment

Time frame: Within 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.